Property:Age groups specification
This is a property of type Text.
V
Mean age (SD) per arm:
Enzyme arm: 51.5 (8.7)
Control arm: 56.4 (6.7) +
Vitale et al. (2020): ZeOxaNMulti Trial: A Randomized, Double-Blinded, Placebo-Controlled Trial of Oral PMA-Zeolite to Prevent Chemotherapy-Induced Side Effects, in Particular, Peripheral Neuropathy +
40.8% < 60 years (Intervention: 50% and placebo: 31.7%) +
W
Walsh et al. (2010): Use of alpha,25-dihydroxyvitamin D3 treatment to stimulate immune infiltration into head and neck squamous cell carcinoma +
Range: 45-92
Intervention arm: mean: 66
Control arm: mean: 63 +
Watanabe et al. (2010): Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer +
Intervention arm: mean: 67.4 (53-78)
Control arm: mean: 62.7 (35-86) +
Williams et al. (1996): Phase III double-blind evaluation of an aloe vera gel as a prophylactic agent for radiation-induced skin toxicity +
? +
Wrbka et al. (1987): Unterstützung der Chemotherapie inoperabler Karzinome durch proteolytische Fermente +
Age groups per arm (n)
Enzyme-arm: 41-50 = 1; 51-60 = 2; 61-70 = 10; 71-80 = 12
Control-arm: 41-50 = 0; 51-60 = 3; 61-70 = 11; 71-80 = 12 +
Wyatt et al. (2012): Health-Related Quality-of-Life Outcomes: A Reflexology Trial With Patients With Advanced-Stage Breast Cancer +
Mean = 56 years +
Wyatt et al. (2017): A Randomized Clinical Trial of Caregiver-Delivered Reflexology for Symptom Management During Breast Cancer Treatment +
Mean (SD):
Reflexology arm: 58.09 (11.62)
Control arm: 54.80 (10.30) +
Y
Yap et al. (2017): Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine-induced hand-foot syndrome: a randomized clinical trial +
Age in years, median (range): 58 (26-82) +
Z
Zalat et al. (2020): Evaluation of the cardioprotective effects of l-carnitine and silymarin in cancer patients receiving anthracycline-containing chemotherapy +
Age Mean ± SD: carnitine arm 45.64 ± 9.941, silymarin arm 44.68 ± 12.44, control arm 44.455 ± 9.47;range 20–60 years +
Zick et al. (2008): Phase II trial of encapsulated ginger as a treatment for chemotherapy-induced nausea and vomiting +
(MW±SD): Placebo: 58.3±12.3, 1.0-g ginger dose-arm: 53.3±12.0, 2.0-g ginger dose: 55.5±11.2 years +
Ö